



Sequella, Incorporated  
9610 Medical Center Drive  
Suite 200  
Rockville, MD 20850  
Tele: 301-762-7776  
Fax: 301-762-7778

## ***NEWS RELEASE***

### **FOR IMMEDIATE RELEASE**

#### **SEQUELLA, INC. AND SANKYO CO., LTD. SIGN WORLDWIDE LICENSING AGREEMENT TO DEVELOP AND MARKET PROMISING NEW ANTI-TUBERCULOSIS COMPOUNDS**

Rockville, Maryland (NOVEMBER 1, 2004) -- Sequella, Inc. today announced that it has entered into an exclusive license agreement for Sankyo's novel anti-tuberculosis translocase inhibitors. These inhibitors represent a potential new class of anti-tuberculosis agents that act through specific inhibition of mycobacterial translocase I, an enzyme required for cell wall synthesis.

Under the agreement, Sankyo has granted Sequella an exclusive license for these compounds in all major markets for tuberculosis and all other potential indications of utility in exchange for downstream milestone and royalty payments.

"We are pleased that Sankyo has chosen Sequella to complete development and commercialization of this exciting new class of compounds," said Carol Nacy, Ph.D., CEO of Sequella, Inc. "Sankyo is a leader and innovator in global healthcare, and this collaboration validates our capabilities in the commercialization of new products for tuberculosis."

Sankyo has completed many preclinical studies of these compounds, including an *in vivo* demonstration of activity in an animal model of tuberculosis as well as preliminary pharmacokinetic and toxicology studies, all of which produced very promising data. Sequella will apply its expertise in the field of tuberculosis to complete the preclinical characterization and development of these compounds with the goal of advancing them to clinical development and commercialization.

#### **About Tuberculosis**

Tuberculosis is the leading single-agent infectious disease killer in the world, as well as being the leading cause of death for people infected with HIV. In the 1990s alone, there were 30 million estimated deaths due to TB, and it is predicted that TB will kill 70-90 million people in the next three decades without new tools to fight the disease. According to the World Health Organization and Harvard School of Public Health, approximately \$4 billion is spent every year on TB control, of which \$2.8 billion is spent by developed countries such as the United States.

## **About Sequella, Inc.**

Sequella, Inc. is a development stage biotechnology company designed to facilitate the translation of concepts that exist at the lab bench into commercial products that can alleviate the global burden of infectious disease. The company, headquartered in Rockville, MD, is focusing its initial research efforts on therapeutics, diagnostics and vaccines to address the growing tuberculosis (TB) problem worldwide. For company information, please visit [www.sequella.com](http://www.sequella.com).

## **About Sankyo**

Sankyo Co., Ltd. of Tokyo, one of Japan's largest pharmaceutical companies, has a long history of discovering new classes of drugs, including the statin class of lipid-lowering drugs. Beginning with its discovery of the first statin, mevastatin, and the co-discovery of lovastatin, the first statin to be marketed, Sankyo has been a pioneer in the cardiovascular disease arena. Additionally, Sankyo discovered, developed, manufactures and markets pravastatin sodium and olmesartan medoximil, an angiotensin II receptor blocker (ARB). For further information about Sankyo and its products, log on to <http://www.sankyo.co.jp/english/>.

### For more information, please contact:

Katherine Sacksteder, Ph.D.  
Director of Communications  
Sequella, Inc.  
9610 Medical Center Drive, Suite 200  
Rockville, MD 20850  
301-762-7776; 301-762-7778 (fax)  
[katherinesacksteder@sequella.com](mailto:katherinesacksteder@sequella.com)